These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2150551)

  • 1. [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
    du Bois A; Meerpohl HG; Wilhelm C; Quaas L; Barnickel I; Pfleiderer A
    Onkologie; 1990 Oct; 13(5):364-8. PubMed ID: 2150551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
    Einhorn LH; Nagy C; Werner K; Finn AL
    J Clin Oncol; 1990 Apr; 8(4):731-5. PubMed ID: 2138214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
    Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
    J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
    Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
    N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
    N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
    Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
    Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron.
    du Bois A; Meerpohl HG; Vach W; Kommoss FG; Fenzl E; Pfleiderer A
    Eur J Cancer; 1992; 28(2-3):450-7. PubMed ID: 1534250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy.
    Seynaeve C; de Mulder PH; Lane-Allman E; van Liessum PA; Verweij J
    Clin Oncol (R Coll Radiol); 1991 Jul; 3(4):199-203. PubMed ID: 1834161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
    Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
    J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting].
    Depierre A
    Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
    Grunberg SM; Stevenson LL; Russell CA; McDermed JE
    J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.